09; Fig 1A); there appeared to be stronger evidence of a differe

09; Fig. 1A); there appeared to be stronger evidence of a difference between groups when adjusted in age, sex, BMI, and diabetes (P = 0.03; Fig. 1B,C). HCC occurred more commonly in HCV than in NAFLD (18 [6.8%] versus 6 [2.4%] respectively; P = 0.03), with time-to-event illustrated in Supporting Fig. 1. There was no significant difference in total vascular events between NAFLD and HCV groups (17 [6.9%] versus 10 [3.8%]; P = 0.17). In the NAFLD cohort, there were a total of 33 deaths or liver transplants (13.4%). Of the see more 14 liver-related deaths and transplantations, 3 were related to HCC; there

were 4 deaths related to other cancers and 1 definite vascular death. The probability of overall survival was 99.6%, 96.7%, and 81.6% at 12, 36, and 120 months, respectively (Fig. 2A). In the HCV cohort, there were a total of 25 deaths or liver transplants (9.5%). Of the 21 liver-related deaths and transplantations, 12 were related to HCC; there was 1 definite vascular death and 3 deaths from unknown causes. The probability of overall free survival was 99.2%, 98.3%, and 82.0% at 12, 36, and 120 months, respectively (Fig. 2A). Overall mortality

was similar in both cohorts (P = 0.38; Fig. 2A), with no evidence of differences after adjustment by differences between groups in age, sex, BMI, diabetes, selleck compound and dyslipidaemia (P = 0.6; Fig. 2B,C). In the NAFLD group, there was strong evidence of differences between fibrosis stage 3 and 4 for total liver-related complications (P < 0.001) and some evidence for overall mortality (P = 0.05), as illustrated in Supporting Fig. 2A,B. In the HCV group, there was little evidence of differences between fibrosis stage 3 and 4 for

total liver-related complications (P = 0.18) and some evidence selleck kinase inhibitor for overall mortality (P = 0.04), as illustrated in Supporting Fig. 3A,B. Univariate models to characterize differences in the NAFLD group are shown in Supporting Table 1, and a summary of the multivariate predictive factors for all categories of outcome are shown in Table 2. Stage 4 fibrosis, past history of coronary heart disease, lower serum levels of cholesterol, lower levels of ALT, and lower platelet count were all independently associated with total liver-related complications. Independent predictors were also identified for the development of ascites (e.g., lower platelet count), encephalopathy (e.g., older age), gastroesophageal varices (e.g., stage 4 fibrosis, lower levels of ALT, lower platelet count, and lower levels of cholesterol), and myocardial infarction (e.g., past medical history of hypercholesterolemia and lower HDL cholesterol). No factors were identified as predictors for HCC or stroke. All these differences remained unaffected when the center variable was included in the models.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>